Olssa (Olmesartan Medoxomil, Amlodipine)

Olssa combines olmesartan medoxomil and amlodipine to address hypertension by targeting the renin‑angiotensin system and vascular smooth‑muscle tone.

• Essential hypertension: provides effective blood‑pressure reduction when monotherapy is insufficient.
• Hypertension with cardiovascular risk: improves blood‑pressure control while offering vascular protection.
• Hypertension in patients requiring combination therapy: simplifies regimen by delivering two antihypertensive agents in a single tablet.

• Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone‑mediated sodium retention. Amlodipine inhibits L‑type calcium channels in vascular smooth muscle, causing arterial dilation. The combined actions reduce systemic vascular resistance and lower cardiac afterload, resulting in sustained blood‑pressure reduction. Both agents have complementary pharmacokinetic profiles, allowing once‑daily dosing and maintaining consistent plasma concentrations throughout the day.

Olssa may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Dizziness: light‑headed sensation, especially after standing.
• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Flushing: transient warmth and redness of skin.
• Fatigue: feeling of tiredness without exertion.
• Palpitations: awareness of heartbeats.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or airway.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Myocardial infarction: chest pain indicative of heart attack.
• Renal impairment: sudden decrease in kidney function.
• Allergic reactions: rash, itching, or anaphylaxis.

When prescribing Olssa, clinicians should consider several safety precautions to minimize risk.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR before and during therapy.
• Electrolyte balance: monitor potassium levels, especially if combined with diuretics.
• Pregnancy contraindication: avoid use during pregnancy due to fetal toxicity risk.
• Hepatic impairment caution: adjust therapy in patients with moderate to severe liver disease.
• Store at room temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Olssa can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: combined renin‑angiotensin blockade increases risk of renal complications.
• ACE inhibitors or other ARBs: additive effect may cause severe hypotension and hyperkalemia.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): raise amlodipine concentrations, increasing toxicity risk.
• Lithium: concurrent use may elevate lithium levels, leading to toxicity.
• NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypotensive response, requiring dose adjustment.
• Beta‑blockers: additive blood‑pressure lowering effect, monitor heart rate.
• Simvastatin: increased risk of myopathy when combined with amlodipine.
• Grapefruit juice: can increase amlodipine plasma levels.
• Rifampin: may reduce amlodipine concentrations, diminishing efficacy.